FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileJasper Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
JSPRW
Jasper Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Jasper Therapeutics, Inc. (JSPRW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisJSPRW
JSPRW
Jasper Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
JSPRW
  1. Home
  2. Stocks
  3. Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc.

🇺🇸JSPRW•NASDAQ

Jasper Therapeutics, Inc.

🇺🇸JSPRW•NASDAQ
Market cap
$3.25K

Your view on JSPRW

Mkt Cap
$3.25K
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Jasper Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Jeet Mahal
Headquarters
2200 Bridge Pkwy, Redwood City, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Jeet Mahal
Headquarters
2200 Bridge Pkwy, Redwood City, CA, US
Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.

The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells.

It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency.

Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Jasper Therapeutics, Inc.. Starting points for Jasper Therapeutics, Inc.: EPS -$0.01, beta 3.00 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Jasper Therapeutics, Inc.. Trailing twelve-month EPS for Jasper Therapeutics, Inc. stands at -$0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026

Buy

Analyst ratings

1 rating
  • Strong Buy0
  • Buy1
  • Hold0
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.44−$0.03−$0.67−$0.73
Lowest estimate−$0.44−$0.03−$0.67−$0.73
Highest estimate−$0.44−$0.03−$0.67−$0.73
Number of analysts1111
A year ago−$0.321−$0.041−$118.501—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$8.00M$8.00M$12.00M$173800.00
Lowest estimate$8.00M$8.00M$12.00M$173800.00
Highest estimate$8.00M$8.00M$12.00M$173800.00
Number of analysts4452
A year ago$0.00$0.00$0.00—
Growth vs a year ago————
Recent rating and target changes (1)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Jasper Therapeutics, Inc.. Jasper Therapeutics, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold JSPRW19 companies
Compare JSPRW with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
AZTRAzitra, Inc.HealthcareBiotechnology$3.1M
ENVBEnveric Biosciences, Inc.HealthcareBiotechnology$6.0M
INDPIndaptus Therapeutics, Inc.HealthcareBiotechnology$319.3M
ONCOOnconetix, Inc.HealthcareBiotechnology$1.0M
PTIXProtagenic Therapeutics, Inc.HealthcareBiotechnology$470,654
REVBRevelation Biosciences, Inc.HealthcareBiotechnology$2.0M
SCNIScinai Immunotherapeutics Ltd.HealthcareBiotechnology$204,191
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
BCTXBriaCell Therapeutics Corp.HealthcareNASDAQ$26.7M
BCTXZBriaCell Therapeutics Corp. WarrantHealthcareNASDAQ$243,944
BCYCBicycle Therapeutics plcHealthcareNASDAQ$203.3M
BDRXBiodexa Pharmaceuticals PlcHealthcareNASDAQ$174,870
BDTXBlack Diamond Therapeutics, Inc.HealthcareNASDAQ$75.3M
BEAMBeam Therapeutics Inc.HealthcareNASDAQ$2.2B
BETR.CNBetterLife Pharma Inc.HealthcareCNQ—
BETRFBetterLife Pharma Inc.HealthcareOTC$6.4M
BHVNBiohaven Ltd.HealthcareNYSE$1.9B
BICTFBiocure Technology Inc.HealthcareOTC$379,088
BIOABioAge Labs, Inc.HealthcareNASDAQ$161.1M
BIOAFBioasis Technologies Inc.HealthcareOTC$15,883
Open Comparable Analysis
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Jasper Therapeutics, Inc. executives and directors. Shares of Jasper Therapeutics, Inc. have traded between $0.0092 and $0.08 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Jasper Therapeutics, Inc.. Coverage tracks Jasper Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Jasper Therapeutics, Inc.

JSPRW AnalysisWeak
Past
1
Growth
2
Health
1
Profit
1
Value
1